February 6, 2019

PET Imaging in Potentially Evolving Treatment Paradigms in Alzheimer’s Disease

Virtual 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Case Study Panel Discussion

In this section, Ana Franceschi, MD, and Paul Schulz, MD, focus on three patient cases in which PET imaging has supported a diagnosis. The first case involves a patient with non-specific cognitive impairment where FDG PET and amyloid PET are used to confirm AD pathology and a diagnosis of AD dementia. In the second case, comprehensive PET imaging (FDG, amyloid, tau) helps to provide an etiologic diagnosis of mild cognitive impairment due to AD in a patient with mild clinical symptoms. The final case illustrates how PET imaging is used to exclude a diagnosis of AD in a patient with behavioral-variant frontotemporal dementia. The section concludes with a brief summary before Tammie Benzinger, MD, PhD, provides her expert insights on the cases.

Key Learning Objectives from Biogen’s SNMMI 2021 Symposium:

  • Provide an understanding of AD by examining its pathophysiology, epidemiology, and the treatment landscape
  • Outline the utility of PET imaging for early diagnosis of AD in the context of emerging anti-amyloid therapies
  • Explore PET findings from recent phase 3 clinical trials and through case study discussion, highlight the importance of PET imaging, and identify best practices for neurologists and radiologists to use PET for the diagnosis of AD

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.